A retrospective single-center study to determine clinical outcomes of tisagenlecleucel in lymphoma patients with predominant management in an ambulatory setting
Latest Information Update: 04 Aug 2022
At a glance
- Drugs Tisagenlecleucel (Primary)
- Indications Lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 04 Aug 2022 New trial record
- 01 Aug 2022 Results published in the Clinical Lymphoma, Myeloma & Leukemia